Skip to main content
CLSDQ logo

CLSDQ · Clearside Biomedical, Inc.

$0.25 +0.00 (+0.00%) At close · Jul 22
Market Cap
$1.30M
Shares
5.23M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.25 Open$0.25 Day$0.25–0.25 52W$0.01–9.30 Avg vol 30d1K Short int96K · 1.8% float · 18.1d Short vol100% Last earningsMar 27, 2025 DataJan 2020–Jul 2026 Filing10-Q · Nov 14

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
filed Nov 14, 2025

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Weak Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 18.6 · elevated Equity put/call 0.79
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −77%
below
Price vs 50-day avg +5%
above
RSI (14) 55
neutral
MACD trend Positive
52-week position 3%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return +126%
trailing
6-month return −76%
trailing
YTD return −65%
this year
Relative strength −83%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow Flat
0% holders QoQ
Insider flow Flat
No net insider activity over 90 days
Short interest Flat
1.83% of float · ▬ 0.0% MoM · 18.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
1 holders — 13F breadth
Fundamentals
Fair
Revenue growth −80%
Y/Y
EPS growth +11%
Y/Y
Free cash flow $-25.7M
Balance sheet $15.2M
net cash
Quant / Vol
risk profile
Very High
Volatility 1640%
annualized · 1-yr
Max drawdown −100%
past year
ATR 14.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
2 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−77% Bearish
Price vs 50-day avg
+5% Bullish
RSI (14)
55 Neutral
MACD trend
Positive Bullish
52-week position
3% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
No clear signal
Trend (MA cross) No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow Flat
0% holders QoQ
Insider flow Flat
No net insider activity over 90 days
Short interest Flat
1.83% of float · ▬ 0.0% MoM · 18.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
1 holders — 13F breadth
Price context
position in its 52-week range
52-wk low $0 Now $0 · 3% 52-wk high $9
vs 200-day avg -77% vs 50-day avg +5%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CLSDQ
Clearside Biomedical, Inc.
this stock
$1.30M -64.7% -95.5% 1.8%
ONC
BeOne Medicines Ltd.
$471.01B +7.6% +22179.2% 958.5 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
$121.16B +4.4% +46.2% 28.3 2.0%
REGN
Regeneron Pharmaceuticals, Inc.
$68.78B -15.4% +20.8% 16.0 3.3%
ARGX
Argenx SE
$57.44B +9.9% 2.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders
Holders
1
% held
0.5%
Net QoQ
0 sh
Top holder
DRW Securities, LLC
Held Float
View
Short & Settlement
Short Interest
Shares short
95.7K
Days to cover
18.1d
Change
0 sh
View
Short Volume
Short vol %
100%
As of
Jul 13, 2026
Short Total
View
Fails to Deliver
FTD shares
6
Value
$1
As of
Jun 17, 2026
View
Off-Exchange
Off-exchange %
99.5%
Week of
May 4, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$1.7M
Net income (FY)
$-34.4M
EPS diluted
$-7.05
View
Filings
SEC Filings
Latest
8-K
Filed
Dec 29, 2025
This year
0
View
Proposed Sales
Value
$22.8K
Shares
18.0K
Filed
Jan 19, 2024
View
Earnings & Events
Earnings Calls
Last call
Mar 27, 2025
View

Performance

5D 20D 120D MTD YTD
CLSDQ +0.0% +126.4% -75.5% +107.5% -64.7%
SPY -1.0% +1.9% +7.5% +0.1% +9.6%
vs SPY +1.0% +124.5% -83.0% +107.4% -74.3%
Key facts CIK 1539029 CUSIP 185063203 Visit website Investor relations